A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1000

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Neoplasms

Interventions

BIOLOGICAL: Amivantamab
BIOLOGICAL: Cetuximab
DRUG: 5-fluorouracil
DRUG: Leucovorin calcium/Levoleucovorin
DRUG: Oxaliplatin
DRUG: Irinotecan Hydrochloride

Sponsor

Janssen Research & Development, LLC